# A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

> **NCT07609914** · PHASE4 · RECRUITING · sponsor: **Pfizer** · enrollment: 400 (estimated)

## Conditions studied

- Acute Treatment of Migraine

## Interventions

- **DRUG:** Rimegepant

## Key facts

- **NCT ID:** NCT07609914
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-28
- **Primary completion:** 2028-06-07
- **Final completion:** 2028-06-07
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07609914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07609914, "A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07609914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
